Glucose-Dependent Insulinotropic Polypeptide Ameliorates Mild Traumatic Brain Injury-Induced Cognitive and Sensorimotor Deficits and Neuroinflammation in Rats

Journal of Neurotrauma

Volumn 33, Issue 22, 2016, Pages 2044-2054

  Yu, Yu Wen ^a   Hsieh, Tsung Hsun ^a,b   Chen, Kai Yun ^a   Wu, John Chung Che ^c   Hoffer, Barry J ^a,d   Greig, Nigel H ^e   Li, Yazhou ^e   Lai, Jing Huei ^a,c   Chang, Cheng Fu ^c   Lin, Jia Wei ^c   Chen, Yu Hsin ^c,f   Yang, Liang Yo ^a,f,h   Chiang, Yung Hsiao ^a,c,g  

^a TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^b CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

^c TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^d CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e NATIONAL INSTITUTE ON AGING   (United States)

^f TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^g TAIPEI MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^h CHINA MEDICAL UNIVERSITY   (Taiwan)

Author keywords

amyloid ; BMX; cognitive dysfunction; controlled cortical impact; GFAP; glucagon like peptide 1; glucose dependent insulinotropic polypeptide; mild traumatic brain injury; neuroinflammation; precursor protein

Indexed keywords

AMYLOID PRECURSOR PROTEIN; BIOLOGICAL MARKER; BONE MARROW TYROSINE KINASE GENE IN CHROMOSOME X; GASTRIC INHIBITORY POLYPEPTIDE; GLIAL FIBRILLARY ACIDIC PROTEIN; UNCLASSIFIED DRUG; AUTACOID;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BALANCE DISORDER; BEHAVIOR; COGNITIVE DEFECT; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG EFFICACY; DRUG MEGADOSE; DRUG TOLERABILITY; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; LOW DRUG DOSE; MALE; MEMORY DISORDER; MILD CONTROLLED CORTICAL IMPACT; MORRIS WATER MAZE TEST; NERVOUS SYSTEM INFLAMMATION; NERVOUS SYSTEM PARAMETERS; NEUROPROTECTION; NEUROTROPISM; NONHUMAN; NOVEL OBJECT RECOGNITION TEST; PROTEIN EXPRESSION; RAT; RECOGNITION; SENSORIMOTOR FUNCTION; SPRAGUE DAWLEY RAT; TASK PERFORMANCE; TRAUMATIC BRAIN INJURY; WALKING; WESTERN BLOTTING; ANIMAL; ANTAGONISTS AND INHIBITORS; BRAIN CONCUSSION; DRUG EFFECTS; HUMAN; INFLAMMATION; METABOLISM; PHYSIOLOGY; PSYCHOLOGY; PSYCHOMOTOR PERFORMANCE; SUBCUTANEOUS DRUG ADMINISTRATION;

ANIMALS; BRAIN CONCUSSION; COGNITIVE DYSFUNCTION; GASTRIC INHIBITORY POLYPEPTIDE; HUMANS; INFLAMMATION; INFLAMMATION MEDIATORS; INJECTIONS, SUBCUTANEOUS; MALE; PSYCHOMOTOR PERFORMANCE; RATS; RATS, SPRAGUE-DAWLEY;

EID: 84996899109     PISSN: 08977151     EISSN: 15579042     Source Type: Journal    
DOI: 10.1089/neu.2015.4229     Document Type: Article

References (107)

1. Hyder, A.A., Wunderlich, C.A., Puvanachandra, P., Gururaj, G., and Kobusingye, O.C. (2007). The impact of traumatic brain injuries: a global perspective. Neuro Rehabilitation 22, 341-353.
2. Faul, M., Xu, L., Wald, M.M., and Coronado, V.G. (2010). Traumatic Brain Injury in the United States: Emergency Department Visits, Hospitalizations and Deaths 2002-2006. Centers for Disease Control and Prevention, NCfIPaC, ed: Atlanta, Ga.
3. Garner, J., and Brett, S.J. (2007). Mechanisms of injury by explosive devices. Anesthesiol. Clin. 25, 147-160, x.
4. Howard, P.K., and Shapiro, S.E. (2011). Diagnosing and treating mild traumatic brain injury in children. Adv. Emerg. Nurs. J. 33, 274-278.
5. Signoretti, S., Vagnozzi, R., Tavazzi, B., and Lazzarino, G. (2010). Biochemical and neurochemical sequelae following mild traumatic brain injury: summary of experimental data and clinical implications. Neurosurg. Focus 29, E1.
6. Arciniegas, D.B., Anderson, C.A., Topkoff, J., and McAllister, T.W. (2005). Mild traumatic brain injury: a neuropsychiatric approach to diagnosis, evaluation, and treatment. Neuropsychiatr. Dis. Treat. 1, 311-327.
7. Ponsford, J., Cameron, P., Fitzgerald, M., Grant, M., and Mikocka-Walus, A. (2011). Long-term outcomes after uncomplicated mild traumatic brain injury: a comparison with trauma controls. J. Neurotrauma 28, 937-946.
8. Marshall, S., Bayley, M., McCullagh, S., Velikonja, D., and Berrigan, L. (2012). Clinical practice guidelines for mild traumatic brain injury and persistent symptoms. Can. Fam. Physician 58, 257-267, e128-140.
9. Levin, H.S. (1998). Cognitive function outcomes after traumatic brain injury. Curr. Opin. Neurol. 11, 643-646.
10. Schultz, B.A., Cifu, D.X., McNamee, S., Nichols, M., and Carne, W. (2011). Assessment and treatment of common persistent sequelae following blast induced mild traumatic brain injury. Neuro Rehabilitation 28, 309-320.
11. Oddy, M., and Humphrey, M. (1980). Social recovery during the year following severe head injury. J. Neurol. Neurosurg. Psychiatry 43, 798-802.
12. Oddy, M., Humphrey, M.. and Uttley, D. (1978). Subjective impairment and social recovery after closed head injury. J. Neurol. Neurosurg. Psychiatry 41, 611-616.
13. Oddy, M., Coughlan, T., Tyerman, A., and Jenkins, D. (1985). Social adjustment after closed head injury: a further follow-up seven years after injury. J. Neurol. Neurosurg. Psychiatry 48, 564-568.
14. Walker, K.R., and Tesco, G. (2013). Molecular mechanisms of cognitive dysfunction following traumatic brain injury. Front. Aging Neurosci. 5, 29.
15. Bramlett, H.M., Green, E.J., and Dietrich, W.D. (1997). Hippocampally dependent and independent chronic spatial navigational deficits following parasagittal fluid percussion brain injury in the rat. Brain Res. 762, 195-202.
16. Dixon, C.E., Kochanek, P.M., Yan, H.Q., Schiding, J.K., Griffith, R.G., Baum, E., Marion, D.W., and DeKosky, S.T. (1999). One-year study of spatial memory performance, brain morphology, and cholinergic markers after moderate controlled cortical impact in rats. J. Neurotrauma 16, 109-122.
17. Lyeth, B.G., Jenkins, L.W., Hamm, R.J., Dixon, C.E., Phillips, L.L., Clifton, G.L., Young, H.F., and Hayes, R.L. (1990). Prolonged memory impairment in the absence of hippocampal cell death following traumatic brain injury in the rat. Brain Res. 526, 249-258.
18. McIntosh, T.K., Juhler, M., and Wieloch, T. (1998). Novel pharmacologic strategies in the treatment of experimental traumatic brain injury: 1998. J. Neurotrauma 15, 731-769.
19. Raghupathi, R., Graham, D.I., and McIntosh, T.K. (2000). Apoptosis after traumatic brain injury. J. Neurotrauma 17, 927-938.
20. Tweedie, D., Milman, A., Holloway, H.W., Li, Y., Harvey, B.K., Shen, H., Pistell, P.J., Lahiri, D.K., Hoffer, B.J., Wang, Y., Pick, C.G., and Greig, N.H. (2007). Apoptotic and behavioral sequelae of mild brain trauma in mice. J. Neurosci. Res. 85, 805-815.
21. Frankola, K.A., Greig, N.H., Luo, W., and Tweedie, D. (2011). Targeting TNF-alpha to elucidate and ameliorate neuroinflammation in neurodegenerative diseases. CNS Neurol. Disord. Drug Targets 10, 391-403.
22. Wu, J.C., Chen, K.Y., Yu, Y.W., Huang, S.W., Shih, H.M., Chiu, W.T., Chiang, Y.H., and Shiau, C.Y. (2012). Location and level of Etk expression in neurons are associated with varied severity of traumatic brain injury. PloS One 7, e39226.
23. Paavonen, K., Ekman, N., Wirzenius, M., Rajantie, I., Poutanen, M. and Alitalo, K. (2004). Bmx tyrosine kinase transgene induces skin hyperplasia, inflammatory angiogenesis, and accelerated wound healing. Mol. Biol. Cell 15, 4226-4233.
24. Helmy, A., Carpenter, K.L., Skepper, J.N., Kirkpatrick, P.J., Pickard, J.D., and Hutchinson, P.J. (2009). Microdialysis of cytokines: methodological considerations, scanning electron microscopy, and determination of relative recovery. J. Neurotrauma 26, 549-561.
25. Palmer, C.D., Mutch, B.E., Workman, S., McDaid, J.P., Horwood, N.J., and Foxwell, B.M. (2008). Bmx tyrosine kinase regulates TLR4-induced IL-6 production in human macrophages independently of p38 MAPK and NFkapp}B activity. Blood 111, 1781-1788.
26. d'Avila, J.C., Lam, T.I., Bingham, D., Shi, J., Won, S.J., Kauppinen, T.M., Massa, S., Liu, J., and Swanson, R.A. (2012). Microglial activation induced by brain trauma is suppressed by post-injury treatment with a PARP inhibitor. J. Neuroinflammation 9, 31.
27. Pelinka, L.E., Kroepfl, A., Leixnering, M., Buchinger, W., Raabe, A., and Redl, H. (2004). GFAP versus S100B in serum after traumatic brain injury: relationship to brain damage and outcome. J. Neurotrauma 21, 1553-1561.
28. Nylen, K., Ost, M., Csajbok, L.Z., Nilsson, I., Blennow, K., Nellgard, B., and Rosengren, L. (2006). Increased serum-GFAP in patients with severe traumatic brain injury is related to outcome. J. Neurol. Sci. 240, 85-91.
29. Vos, P.E., Jacobs, B., Andriessen, T.M., Lamers, K.J., Borm, G.F., Beems, T., Edwards, M., Rosmalen, C.F., and Vissers, J.L. (2010). GFAP and S100B are biomarkers of traumatic brain injury: an observational cohort study. Neurology 75, 1786-1793.
30. Sofroniew, M.V., and Vinters, H.V. (2010). Astrocytes: biology and pathology. Acta Neuropathol. 119, 7-35.
31. Pike, C.J., Cummings, B.J., and Cotman, C.W. (1995). Early association of reactive astrocytes with senile plaques in Alzheimer's disease. Exp. Neurol. 132, 172-179.
32. Verkhratsky, A., Olabarria, M., Noristani, H.N., Yeh, C.Y., and Rodriguez, J.J. (2010). Astrocytes in Alzheimer's disease. Neurotherapeutics 7, 399-412.
33. Funato, H., Yoshimura, M., Yamazaki, T., Saido, T.C., Ito, Y., Yokofujita, J., Okeda, R., and Ihara, Y. (1998). Astrocytes containing amyloid beta-protein (Abeta)-positive granules are associated with Abeta40-positive diffuse plaques in the aged human brain. Am. J. Pathol. 152, 983-992.
34. Wyss-Coray, T., Loike, J.D., Brionne, T.C., Lu, E., Anankov, R., Yan, F., Silverstein, S.C., and Husemann, J. (2003). Adult mouse astrocytes degrade amyloid-beta in vitro and in situ. Nat. Med. 9, 453-457.
35. Gentleman, S.M., Nash, M.J., Sweeting, C.J., Graham, D.I., and Roberts, G.W. (1993). Beta-amyloid precursor protein (beta APP) as a marker for axonal injury after head injury. Neurosci. Lett. 160, 139-144.
36. Otsuka, N., Tomonaga, M., and Ikeda, K. (1991). Rapid appearance of beta-amyloid precursor protein immunoreactivity in damaged axons and reactive glial cells in rat brain following needle stab injury. Brain Res. 568, 335-338.
37. Janus, C., Phinney, A.L., Chishti, M.A., and Westaway, D. (2001). New developments in animal models of Alzheimer's disease. Curr. Neurol. Neurosci. Rep. 1, 451-457.
38. Kraus, M.F., Susmaras, T., Caughlin, B.P., Walker, C.J., Sweeney, J.A., and Little, D.M. (2007). White matter integrity and cognition in chronic traumatic brain injury: a diffusion tensor imaging study. Brain 130, 2508-2519.
39. Johnson, V.E., Stewart, W., and Smith, D.H. (2013). Axonal pathology in traumatic brain injury. Exp. Neurol. 246, 35-43.
40. Ekmark-Lewen, S., Flygt, J., Kiwanuka, O., Meyerson, B.J., Lewen, A., Hillered, L., and Marklund, N. (2013). Traumatic axonal injury in the mouse is accompanied by a dynamic inflammatory response, astroglial reactivity and complex behavioral changes. J. Neuroin-flammation 10, 44.
41. Gao, X., and Chen, J. (2011). Mild traumatic brain injury results in extensive neuronal degeneration in the cerebral cortex. J. Neuropathol. Exp Neurol 70, 183-191.
42. Lee, Y.K., Hou, S.W., Lee, C.C., Hsu, C.Y., Huang, Y.S., and Su, Y.C. (2013). Increased risk of dementia in patients with mild traumatic brain injury: a nationwide cohort study. PloS One 8, e62422.
43. Salcedo, I., Tweedie, D., Li, Y., and Greig, N.H. (2012). Neuroprotective and neurotrophic actions of glucagon-like peptide-1: an emerging opportunity to treat neurodegenerative and cerebrovascular disorders. Br. J. Pharmacol. 166, 1586-1599.
44. Greig, N.H., Tweedie, D., Rachmany, L., Li, Y., Rubovitch, V., Schreiber, S., Chiang, Y.H., Hoffer, B.J., Miller, J., Lahiri, D.K., Sambamurti, K., Becker, R.E., and Pick, C.G. (2014). Incretin mimetics as pharmacologic tools to elucidate and as a new drug strategy to treat traumatic brain injury. Alzheimers Dement. 10, Suppl 1, S62-S75.
45. Rachmany, L., Tweedie, D., Li, Y., Rubovitch, V., Holloway, H.W., Miller, J., Hoffer, B.J., Greig, N.H., and Pick, C.G. (2013). Exendin- 4 induced glucagon-like peptide-1 receptor activation reverses behavioral impairments of mild traumatic brain injury in mice. Age 35, 1621-1636.
46. Tweedie, D., Rachmany, L., Rubovitch, V., Lehrmann, E., Zhang, Y., Becker, K.G., Perez, E., Miller, J., Hoffer, B.J., Greig, N.H., and Pick, C.G. (2013). Exendin-4, a glucagon-like peptide-1 receptor agonist prevents mTBI-induced changes in hippocampus gene expression and memory deficits in mice. Exp. Neurol. 239, 170-182.
47. Campbell, J.E., and Drucker, D.J. (2013). Pharmacology, physiology, and mechanisms of incretin hormone action. Cell Metab. 17, 819-837.
48. Wu, T., Rayner, C.K., and Horowitz, M. (2016). Incretins. Handb. Exp. Pharmacol. 233, 137-171.
49. Tan, T. and Bloom, S. (2013). Gut hormones as therapeutic agents in treatment of diabetes and obesity. Curr. Opin. Pharmacol. 13, 996-1001.
50. Gault, V.A., Kerr, B.D., Irwin, N., and Flatt, P.R. (2008). C-terminal mini-PEGylation of glucose-dependent insulinotropic polypeptide exhibits metabolic stability and improved glucose homeostasis in dietary-induced diabetes. Biochem. Pharmacol. 75, 2325-2333.
51. Paratore, S., Ciotti, M.T., Basille, M., Vaudry, D., Gentile, A., Parenti, R., Calissano, P., and Cavallaro, S. (2011). Gastric inhibitory polypeptide and its receptor are expressed in the central nervous system and support neuronal survival. Cent. Nerv. System. Agents Med. Chem. 11, 210-222.
52. Lin, C.M., Lin, J.W., Chen, Y.C., Shen, H.H., Wei, L., Yeh, Y.S., Chiang, Y.H., Shih, R., Chiu, P.L., Hung, K.S., Yang, L.Y., and Chiu, W.T. (2009). Hyaluronic acid inhibits the glial scar formation after brain damage with tissue loss in rats. Surg. Neurol. 72, Suppl 2, S50-S54.
53. Wenk, G.L. (2004). Assessment of spatial memory using the radial arm maze and Morris water maze. Curr. Protoc. Neurosci. Chapter 8, Unit 8.5A.
54. Prusky, G.T., West, P.W., and Douglas, R.M. (2000). Reduced visual acuity impairs place but not cued learning in the Morris water task. Behav Brain Res 116, 135-140.
55. Taglialatela, G., Hogan, D., Zhang, W.R., and Dineley, K.T. (2009). Intermediate-and long-term recognition memory deficits in Tg2576 mice are reversed with acute calcineurin inhibition. Behav. Brain Res. 200, 95-99.
56. Dixon, C.E., Lyeth, B.G., Povlishock, J.T., Findling, R.L., Hamm, R.J., Marmarou, A., Young, H.F., and Hayes, R.L. (1987). A fluid percussion model of experimental brain injury in the rat. J. Neurosurg. 67, 110-119.
57. Barth, T.M., Jones, T.A., and Schallert, T. (1990). Functional subdivisions of the rat somatic sensorimotor cortex. Behav. Brain Res. 39, 73-95.
58. Darsalia, V., Larsson, M., Nathanson, D., Klein, T., Nystrom, T., and Patrone, C. (2015). Glucagon-like receptor 1 agonists and DPP-4 inhibitors: potential therapies for the treatment of stroke. J. Cereb. Blood Flow Metab. 35, 718-723.
59. Li, Y., Tweedie, D., Mattson, M.P., Holloway, H.W., and Greig, N.H. (2010). Enhancing the GLP-1 receptor signaling pathway leads to proliferation and neuroprotection in human neuroblastoma cells. J. Neurochem. 113, 1621-1631.
60. Perry, T., Lahiri, D.K., Chen, D., Zhou, J., Shaw, K.T., Egan, J.M., and Greig, N.H. (2002). A novel neurotrophic property of glucagonlike peptide 1: a promoter of nerve growth factor-mediated differentiation in PC12 cells. J. Pharmacol. Exp. Ther. 300, 958-966.
61. Li, Y., Perry, T., Kindy, M.S., Harvey, B.K., Tweedie, D., Holloway, H.W., Powers, K., Shen, H., Egan, J.M., Sambamurti, K., Brossi, A., Lahiri, D.K., Mattson, M.P., Hoffer, B.J., Wang, Y., and Greig, N.H. (2009). GLP-1 receptor stimulation preserves primary cortical and dopaminergic neurons in cellular and rodent models of stroke and Parkinsonism. Proc. Natl. Acad. Sci. U. S. A. 106, 1285-1290.
62. Deacon, C.F., Nauck, M.A., Meier, J., Hucking, K., and Holst, J.J. (2000). Degradation of endogenous and exogenous gastric inhibitory polypeptide in healthy and in type 2 diabetic subjects as revealed using a new assay for the intact peptide. J. Clin. Endocrinol. Metab. 85, 3575-3581.
63. Nauck, M.A., Heimesaat, M.M., Orskov, C., Holst, J.J., Ebert, R., and Creutzfeldt, W. (1993). Preserved incretin activity of glucagonlike peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus. J. Clin. Invest. 91, 301-307.
64. Finan, B., Ma, T., Ottaway, N., Muller, T.D., Habegger, K.M., Heppner, K.M., Kirchner, H., Holland, J., Hembree, J., Raver, C., Lockie, S.H., Smiley, D.L., Gelfanov, V., Yang, B., Hofmann, S., Bruemmer, D., Drucker, D.J., Pfluger, P.T., Perez-Tilve, D., Gidda, J., Vignati, L., Zhang, L., Hauptman, J.B., Lau, M., Brecheisen, M., Uhles, S., Riboulet, W., Hainaut, E., Sebokova, E., Conde-Knape, K., Konkar, A., DiMarchi, R.D., and Tschop, M.H. (2013). Unimolecular dual incretins maximize metabolic benefits in rodents, monkeys, and humans. Sci. Transl. Med. 5, 209ra151.
65. Eakin, K., Li, Y., Chiang, Y.H., Hoffer, B.J., Rosenheim, H., Greig, N.H., and Miller, J.P. (2013). Exendin-4 ameliorates traumatic brain injury-induced cognitive impairment in rats. PloS One 8, e82016.
66. Li, Y., Bader, M., Tamargo, I., Rubovitch, V., Tweedie, D., Pick, C.G. and Greig, N.H. (2015). Liraglutide is neurotrophic and neuroprotective in neuronal cultures and mitigates mild traumatic brain injury in mice. J. Neurochem. 135, 1203-1217.
67. Hakon, J., Ruscher, K., Romner, B., and Tomasevic, G. (2015). Preservation of the blood brain barrier and cortical neuronal tissue by liraglutide, a long acting glucagon-like-1 analogue, after experimental traumatic brain injury. PloS One 10, e0120074.
68. Monami, M., Marchionni, N., and Mannucci, E. (2009). Glucagonlike peptide-1 receptor agonists in type 2 diabetes: a meta-analysis of randomized clinical trials. Eur. J. Endocrinol. 160, 909-917.
69. Nyberg, J., Anderson, M.F., Meister, B., Alborn, A.M., Strom, A.K., Brederlau, A., Illerskog, A.C., Nilsson, O., Kieffer, T.J., Hietala, M.A., Ricksten, A., and Eriksson, P.S. (2005). Glucosedependent insulinotropic polypeptide is expressed in adult hippocampus and induces progenitor cell proliferation. J. Neurosci. 25, 1816-1825.
70. Faivre, E., Gault, V.A., Thorens, B., and Holscher, C. (2011). Glucose-dependent insulinotropic polypeptide receptor knockout mice are impaired in learning, synaptic plasticity, and neurogenesis. J. Neurophysiol. 105, 1574-1580.
71. Figueiredo, C.P., Pamplona, F.A., Mazzuco, T.L., Aguiar, A.S., Jr., Walz, R., and Prediger, R.D. (2010). Role of the glucose-dependent insulinotropic polypeptide and its receptor in the central nervous system: therapeutic potential in neurological diseases. Behav. Pharmacol. 21, 394-408.
72. Ding, K.H., Zhong, Q., Xie, D., Chen, H.X., Della-Fera, M.A., Bollag, R.J., Bollag, W.B., Gujral, R., Kang, B., Sridhar, S., Baile, C., Curl, W., and Isales, C.M. (2006). Effects of glucose-dependent insulinotropic peptide on behavior. Peptides 27, 2750-2755.
73. Tian, J.Q., Wang, Y., Lin, N., Guo, Y.J., Sun, S.H., and Zou, D.J. (2010). Active immunization with glucose-dependent insulinotropic polypeptide vaccine influences brain function and behaviour in rats. Scand. J. Immunol. 72, 1-7.
74. Okawa, T., Kamiya, H., Himeno, T., Seino, Y., Tsunekawa, S., Hayashi, Y., Harada, N., Yamada, Y., Inagaki, N., Seino, Y., Oiso, Y., and Nakamura, J. (2014). Sensory and motor physiological functions are impaired in gastric inhibitory polypeptide receptordeficient mice. J. Diabetes Investig. 5, 31-37.
75. Buhren, B.A., Gasis, M., Thorens, B., Muller, H.W., and Bosse, F. (2009). Glucose-dependent insulinotropic polypeptide (GIP) and its receptor (GIPR): cellular localization, lesion-affected expression, and impaired regenerative axonal growth. J. Neurosci. Res. 87, 1858-1870.
76. Gault, V.A., and Holscher, C. (2008). Protease-resistant glucosedependent insulinotropic polypeptide agonists facilitate hippocampal LTP and reverse the impairment of LTP induced by beta-amyloid. J. Neurophysiol. 99, 1590-1595.
77. Holscher, C. (2014). The incretin hormones glucagonlike peptide 1 and glucose-dependent insulinotropic polypeptide are neuroprotective in mouse models of Alzheimer's disease. Alzheimers Dement. 10, Suppl 1, S47-S54.
78. Atkins, C.M., Oliva, A.A., Jr., Alonso, O.F., Pearse, D.D., Bramlett, H.M., and Dietrich, W.D. (2007). Modulation of the cAMP signaling pathway after traumatic brain injury. Exp. Neurol. 208, 145-158.
79. Li, Y., Duffy, K.B., Ottinger, M.A., Ray, B., Bailey, J.A., Holloway, H.W., Tweedie, D., Perry, T., Mattson, M.P., Kapogiannis, D., Sambamurti, K., Lahiri, D.K., and Greig, N.H. (2010). GLP-1 receptor stimulation reduces amyloid-beta peptide accumulation and cytotoxicity in cellular and animal models of Alzheimer's disease. J. Alzheimers Dis. 19, 1205-1219.
80. Li, Y., Chigurupati, S., Holloway, H.W., Mughal, M., Tweedie, D., Bruestle, D.A., Mattson, M.P., Wang, Y., Harvey, B.K., Ray, B., Lahiri, D.K., and Greig, N.H. (2012). Exendin-4 ameliorates motor neuron degeneration in cellular and animal models of amyotrophic lateral sclerosis. PloS One 7, e32008.
81. Kamoi, K., Shinozaki, Y., Furukawa, K., and Sasaki, H. (2012). Potential correlation between plasma total GIP levels and body mass index in Japanese patients with types 1 or 2 diabetes mellitus. Endocr. J. 59, 353-363.
82. Meier, J.J., Nauck, M.A., Kranz, D., Holst, J.J., Deacon, C.F., Gaeckler, D., Schmidt, W.E., and Gallwitz, B. (2004). Secretion, degradation, and elimination of glucagon-like peptide 1 and gastric inhibitory polypeptide in patients with chronic renal insufficiency and healthy control subjects. Diabetes 53, 654-662.
83. Irwin, N., Green, B.D., Gault, V.A., Greer, B., Harriott, P., Bailey, C.J., Flatt, P.R., and O'Harte, F.P. (2005). Degradation, insulin secretion, and antihyperglycemic actions of two palmitate-derivitized N-terminal pyroglutamyl analogues of glucose-dependent insulinotropic polypeptide. J. Med. Chem. 48, 1244-1250.
84. Martin, C.M., Irwin, N., Flatt, P.R., and Gault, V.A. (2013). A novel acylated form of (d-Ala(2))GIP with improved antidiabetic potential, lacking effect on body fat stores. Biochim. Biophys. Acta 1830, 3407-3413.
85. Tatarkiewicz, K., Hargrove, D.M., Jodka, C.M., Gedulin, B.R., Smith, P.A., Hoyt, J.A., Lwin, A., Collins, L., Mamedova, L., Levy, O.E., D'Souza, L., Janssen, S., Srivastava, V., Ghosh, S.S., and Parkes, D.G. (2014). A novel long-acting glucose-dependent insulinotropic peptide analogue: enhanced efficacy in normal and diabetic rodents. Diabetes Obes. Metab. 16, 75-85.
86. Herman, G.A., Bergman, A., Stevens, C., Kotey, P., Yi, B., Zhao, P., Dietrich, B., Golor, G., Schrodter, A., Keymeulen, B., Lasseter, K.C., Kipnes, M.S., Snyder, K., Hilliard, D., Tanen, M., Cilissen, C., De Smet, M., de Lepeleire, I., Van Dyck, K., Wang, A.Q., Zeng, W., Davies, M.J., Tanaka, W., Holst, J.J., Deacon, C.F., Gottesdiener, K.M., and Wagner, J.A. (2006). Effect of single oral doses of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on incretin and plasma glucose levels after an oral glucose tolerance test in patients with type 2 diabetes. J. Clin Endocrinol. Metab. 91, 4612-4619.
87. Meneilly, G.S., Greig, N., Tildesley, H., Habener, J.F., Egan, J.M., and Elahi, D. (2003). Effects of 3 months of continuous subcutaneous administration of glucagon-like peptide 1 in elderly patients with type 2 diabetes. Diabetes Care 26, 2835-2841.
88. Elahi, D., Ruff, D.A., Carlson, O.D., Meneilly, G.S., Habener, J.F., and Egan, J.M. (2015). Does GLP-1 suppress its own basal secretion? Endocr. Res, 1-5.
89. Gardner, R.C., and Yaffe, K. (2015). Epidemiology of mild traumatic brain injury and neurodegenerative disease. Mol. Cell Neurosci. 66, 75-80.
90. Gardner, R.C., Burke, J.F., Nettiksimmons, J., Kaup, A., Barnes, D.E., and Yaffe, K. (2014). Dementia risk after traumatic brain injury vs nonbrain trauma: the role of age and severity. JAMA Neurol. 71, 1490-1497.
91. Graves, A.B., White, E., Koepsell, T.D., Reifler, B.V., van Belle, G., Larson, E.B., and Raskind, M. (1990). The association between head trauma and Alzheimer's disease. Am. J. Epidemiol. 131, 491-501.
92. Nordstrom, P., Michaelsson, K., Gustafson, Y., and Nordstrom, A. (2014). Traumatic brain injury and young onset dementia: a nationwide cohort study. Ann. Neurol. 75, 374-381.
93. Schofield, P.W., Tang, M., Marder, K., Bell, K., Dooneief, G., Chun, M., Sano, M., Stern, Y., and Mayeux, R. (1997). Alzheimer's disease after remote head injury: an incidence study. J. Neurol. Neurosurg. Psychiatry 62, 119-124.
94. Perry, V.H., Nicoll, J.A., and Holmes, C. (2010). Microglia in neurodegenerative disease. Nat. Rev. Neurol. 6, 193-201.
95. Kumar, A., and Loane, D.J. (2012). Neuroinflammation after traumatic brain injury: opportunities for therapeutic intervention. Brain Behav. Immun. 26, 1191-1201.
96. Cerecedo-Lopez, C.D., Kim-Lee, J.H., Hernandez, D., Acosta, S.A., and Borlongan, C.V. (2014). Insulin-associated neuroinflammatory pathways as therapeutic targets for traumatic brain injury. Med. Hypotheses 82, 171-174.
97. Lozano, D., Gonzales-Portillo, G.S., Acosta, S., de la Pena, I., Tajiri, N., Kaneko, Y., and Borlongan, C.V. (2015). Neuroinflammatory responses to traumatic brain injury: etiology, clinical consequences, and therapeutic opportunities. Neuropsychiatr. Dis. Treat. 11, 97-106.
98. Lloyd, E., Somera-Molina, K., Van Eldik, L.J., Watterson, D.M., and Wainwright, M.S. (2008). Suppression of acute proinflammatory cytokine and chemokine upregulation by post-injury administration of a novel small molecule improves long-term neurologic outcome in a mouse model of traumatic brain injury. J. Neuroinflammation 5, 28.
99. Acosta, S.A., Tajiri, N., Shinozuka, K., Ishikawa, H., Grimmig, B., Diamond, D.M., Sanberg, P.R., Bickford, P.C., Kaneko, Y., and Borlongan, C.V. (2013). Long-term upregulation of inflammation and suppression of cell proliferation in the brain of adult rats exposed to traumatic brain injury using the controlled cortical impact model. PloS One 8, e53376.
100. Acosta, S.A., Diamond, D.M., Wolfe, S., Tajiri, N., Shinozuka, K., Ishikawa, H., Hernandez, D.G., Sanberg, P.R., Kaneko, Y., and Borlongan, C.V. (2013). Influence of post-traumatic stress disorder on neuroinflammation and cell proliferation in a rat model of traumatic brain injury. PloS One 8, e81585.
101. Spielman, L.J., and Klegeris, A. (2014). The role of insulin and incretins in neuroinflammation and neurodegeneration. Immunoendocrinology 1, e391.
102. Lindsay, J.S., and Andis, K. (2014). The role of insulin and incretins in neuroinflammation and neurodegeneration. Immunoendocrinol. 1, e391.
103. Tweedie, D., Ferguson, R.A., Fishman, K., Frankola, K.A., Van Praag, H., Holloway, H.W., Luo, W., Li Y., Caracciolo, L., Russo, I., Barlati, S., Ray, B., Lahiri, D.K., Bosetti, F., Greig, N.H., and Rosi, S. (2012) Tumor necrosis factor-a synthesis inhibitor 3,6¢- dithiothalidomide attenuates markers of inflammation, Alzheimer pathology and behavioral deficits in animal models of neuroin-flammation and Alzheimer's disease. J. Neuroinflammation. 9, 106.
104. Kobori, N., Moore, A.N., and Dash, P.K. (2015). Altered regulation of protein kinase a activity in the medial prefrontal cortex of normal and brain-injured animals actively engaged in a working memory task. J. Neurotrauma 32, 139-148.
105. Titus, D.J., Furones, C., Kang, Y., and Atkins, C.M. (2013). Agedependent alterations in cAMP signaling contribute to synaptic plasticity deficits following traumatic brain injury. Neuroscience 231, 182-194.
106. Kim, S.J., Nian, C., Widenmaier, S., and McIntosh, C.H. (2008). Glucose-dependent insulinotropic polypeptide-mediated upregulation of beta-cell antiapoptotic Bcl-2 gene expression is coordinated by cyclic AMP (cAMP) response element binding protein (CREB) and cAMP-responsive CREB coactivator 2. Mol. Cell. Biol. 28, 1644-1656.
107. Lennox, R.R., Moffett, C., Porter, D.W., Irwin, N., Gault, V.A., and Flatt, P.R. (2015). Effects of glucose-dependent insulinotropic polypeptide receptor knockout and a high-fat diet on cognitive function and hippocampal gene expression in mice. Mol. Med. Rep. 12, 1544-1548.